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Research
Pressure relieving support surfaces (PRESSURE) trial: cost
effectiveness analysis
Cynthia Iglesias, Jane Nixon, Gillian Cranny, E Andrea Nelson, Kim Hawkins, Angela Phillips, David Torgerson, Su
Mason, Nicky Cullum, on behalf of the PRESSURE Trial Group
Abstract
Objective To assess the cost effectiveness of alternating
pressure mattresses compared with alternating pressure
overlays for the prevention of pressure ulcers in patients
admitted to hospital.
Design Cost effectiveness analysis carried out alongside the
pressure relieving support surfaces (PRESSURE) trial; a
multicentre UK based pragmatic randomised controlled trial.
Setting 11 hospitals in six UK NHS trusts.
Participants Intention to treat population comprising 1971
participants.
Main outcome measures Kaplan Meier estimates of restricted
mean time to development of pressure ulcers and total costs for
treatment in hospital.
Results Alternating pressure mattresses were associated with
lower overall costs (£283.6 per patient on average, 95%
confidence interval − £377.59 to £976.79) mainly due to
reduced length of stay in hospital, and greater benefits (a delay
in time to ulceration of 10.64 days on average, − 24.40 to 3.09).
The differences in health benefits and total costs for hospital
stay between alternating pressure mattresses and alternating
pressure overlays were not statistically significant; however, a
cost effectiveness acceptability curve indicated that on average
alternating pressure mattresses compared with alternating
pressure overlays were associated with an 80% probability of
being cost saving.
Conclusion Alternating pressure mattresses for the prevention
of pressure ulcers are more likely to be cost effective and are
more acceptable to patients than alternating pressure overlays.
Introduction
Older age, reduced mobility, impaired nutrition, vascular disease,
faecal incontinence, and skin damage consistently emerge as risk
factors for pressure ulcers.1 2 The annual cost to the UK NHS of
implementing the current guidelines for the treatment of
pressure ulcers was estimated in the region of £1.4b to £2.1b at
2000 prices.3 Experts differ in their views as to the extent to
which pressure ulceration is preventable4; however most would
agree that pressure ulcers are often the consequence of poor
preventive strategies. Between April 2002 and April 2004, the
NHS Litigation Authority (www.nhsla.com/home.htm) received
56 claims for pressure damage (NHS Litigation Authority,
personal communication, 2005), these included four instances
where the patient died. The average cost of a claim was reported
as £37 295 ($70 453; €54 713) but ranged up to £375 000. Inad-
equate nursing care, lack of assistance and care, and failure or
delay in diagnosis were often cited as causal. Early identification
of vulnerable people and timely provision of a cost effective pro-
gramme for the prevention of pressure ulceration in hospitals
could prevent this cost to the NHS and the adverse health conse-
quences of those affected.
Current National Institute for Health and Clinical Excellence
guidelines on the prevention of pressure ulcers recommend the
use of high specification foam mattress as the standard in
vulnerable patients and surfaces such as alternating pressure
mattresses for high risk people.5 This latter recommendation was
based on expert opinion in the absence of research. Alternating
pressure surfaces are available as whole mattress replacement
systems (typically costing about £4000) and as overlays (typically
£1000), which are placed on top of a standard hospital mattress.
The relative costs and effects of these different systems are
uncertain. We carried out an economic evaluation alongside a
large multicentre pragmatic randomised controlled trial of alter-
nating pressure mattresses and alternating pressure overlays.
The clinical results of the trial are published in the accompany-
ing paper.6
Methods
Full details of the trial’s methods are available elsewhere.7 Briefly,
eligible people were aged at least 55 years who were admitted to
vascular, orthopaedic, medical, or care of the elderly wards, either
as acute or elective admissions, in the previous 24 hours.
Inclusion criteria were an expected length of stay of at least seven
days, and an expected (if elective) or actual limitation of activities
and mobility or an existing pressure ulcer of grade 2, or both.
Trial completion was defined as improved mobility and activity,
resolution of pressure ulcers for three consecutive days, transfer
to non-participating wards or consultants, discharge from hospi-
tal, 60 days from randomisation, or death.
Interventions
Participants were randomised to receive an alternating pressure
mattress or an alternating pressure overlay within 24 hours of
hospital admission, using a remote telephone randomisation
service providing concealed allocation. Rather than restrict the
evaluation to prespecified products, we developed specifications
for eligible surfaces to permit the hospitals to use mattresses and
overlays from their existing stock or within their current rental
contract (see Nixon et al6).
Study design
We carried out an economic evaluation analysis in the intention
to treat population of the pressure relieving support surfaces
Cite this article as: BMJ, doi:10.1136/bmj.38850.711435.7C (published 1 June 2006)
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(PRESSURE) trial.6 We estimated the mean health benefits and
mean total costs associated with both surfaces.8 9
Data collection
To estimate the number of pressure ulcer free days, we recorded
the time taken for the development of a new grade 2 pressure
ulcer for each patient. To estimate average length of stay in hos-
pital, we routinely recorded the dates of entry and discharge
from hospital for each patient. We did not record use of wound
dressings as the clinical research nurses routinely observed
patients with pressure ulcers up to grade 2 were not receiving
wound dressings.
Unit costs
Table 1 provides a description of the unit costs. We calculated
hospital treatment costs per day on the basis of estimates from
the Chartered Institute of Public Finance and Accountancy of
the cost per patient day in a care of elderly people, orthopaedic,
or general surgery ward.10 The unit purchasing and rental costs
of each surface were estimated on the basis of UK retail prices
provided by the manufacturers (Huntleigh Healthcare and Hill-
Rom). Patients were assumed to have remained on the allocated
surface during their entire hospital stay. No robust evidence of
the expected life span of the alternating pressure devices was
available; however, clinical experts suggested that adequately
used and maintained surfaces could last from two to seven years,
provided they were not in constant use. For the base case analy-
sis we assumed a two year life span. The pricing year was 2002-3.
Heath outcomes
We defined health benefit as the difference in the mean time to
develop a pressure ulcer between the groups—that is, pressure
ulcer free days. Survival analysis was used to calculate the
restricted Kaplan Meier estimates of mean time to pressure ulcer
development in each trial arm.
Cost effectiveness analysis
We carried out a cost effectiveness analysis, from the perspective
of the UK NHS and Personal Social Service, on the intention to
treat population for the period of hospital stay.11 The time hori-
zon was shorter than one year—that is, the actual duration of
hospital stay, consequently neither costs nor benefits were
discounted.
To account for the skewed nature of data for costs and length
of stay, we used generalised linear models to estimate the mean
difference in overall hospital costs between the mattress and
overlay groups. We used the Akaike Information criterion and
the normal plot of deviance residuals to compare models assum-
ing different distributions functions (Gaussian, gamma, inverse
Gaussian) and link functions (identity, log).12 The final model
assumed a gamma distribution for the data with an identity link
function.13 The coefficient estimates of a generalised linear
model with an identity link function represent the difference
between groups using arithmetic means. To preserve the correla-
tion between health benefits and overall hospital cost, we used
non-parametric bootstrapping techniques to estimate the bias
corrected 95% confidence intervals of the mean differences in
time to development of pressure ulcers and costs between the
overlay and mattress groups.14 We used Stata version 8 for all sta-
tistical analyses.
Sensitivity analysis
The robustness of the results was explored in three different sce-
narios: both devices assumed to be rented rather than
purchased, a five year life span for both devices, and a seven year
life span for both devices.
Results
A total of 1972 participants were randomised from 10 of the 11
hospitals participating in the randomised controlled trial
comparing alternating pressure mattresses with alternating
pressure overlays for the prevention of pressure ulcers. One
patient who had been inadvertently randomised twice was
excluded, leaving an intention to treat population of 1971
participants.
Cost and health benefits
In the base case analysis the generalised linear model which best
described overall hospital costs indicated that on average the
mattress group resulted in a mean reduction in total hospital
cost of £283.60 (95% confidence interval − £377.59 to £976.79,
P = 0.418; table 2). This difference was not statistically significant.
The difference in Kaplan Meier restricted estimates of the
mean time to development of pressure ulcers indicated that par-
ticipants in the mattress group took 10.64 days longer to develop
a pressure ulcer than participants in the overlay group (table 3).
Table 1 Description of unit costs associated with using alternating pressure








165.00 Health service database 2003, Chartered Institute of
Public Finance and Accountancy
Orthopaedic 385.00 Health service database 2003, Chartered Institute of
Public Finance and Accountancy
Vascular 374.00 Health service database 2003, Chartered Institute of
Public Finance and Accountancy
Surface costs:
Overlay 1 010.50 Huntleigh and Hill-Rom retail price list
Mattress 4173.60 Huntleigh and Hill-Rom retail price list
Daily cost of overlay:
2 year life span 1.38 Based on estimates of average unit cost provided by
manufacturers
5 year life span 0.55 Based on estimates of average unit cost provided by
manufacturers
7 year life span 0.40 Based on estimates of average unit cost provided by
manufacturers
Daily cost of mattress:
2 year life span 5.71 Based on estimates of average unit cost provided by
manufacturers
5 year life span 2.25 Based on estimates of average unit cost provided by
manufacturers




Overlay 8.23 Huntleigh and Hill-Rom retail price list
Replacement 16.30 Huntleigh and Hill-Rom retail price list
Table 2 Means (standard deviations) of cost estimates (£) of using
alternating pressure overlays or alternating pressure mattresses for the
prevention of pressure ulcers in patients admitted to hospital
Item Overlay Mattress
Resource use:
Length of stay 20.36 (25.72) 19.14 (21.54)
Hospital costs:
Base case 6793.33 (8196.52) 6509.73 (7347.56)
Rental 6967.81 (8357.40) 6747.48 (7558.25)
Five year life span of
device
6776.43 (8177.07) 6443.49 (7278.95)
Seven year life span of
device
6773.38 (8173.56) 6431.62 (7266.67)
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This difference was not, however, statistically significant (95%
bias corrected confidence interval − 24.40 to 3.09 days).
Cost effectiveness analysis
The base case economic analysis indicated that the mattresses
are a dominant strategy when compared with the overlays; they
are associated with a delay in the development of pressure ulcers
and lower hospital costs. The sampling uncertainty associated
with this result was investigated in an incremental cost effective-
ness plane. Figure 1 shows the results of 1000 replicates of a
non-parametric bootstrap of the estimated mean difference in
cost and benefits. The majority of point estimates fall in the
north west and south west quadrants of the cost effectiveness
plane, suggesting that the overlays are associated with a more
rapid development of pressure ulcers than are the mattresses.
Figure 2 is a cost effectiveness acceptability curve that repre-
sents the uncertainty associated with the decision to consider the
mattresses a dominant alternative when compared with the
overlays. The mattresses are associated with an 80% probability
of being cost saving (the probability associated with a willingness
to pay of zero) compared with the overlay. Similarly, a probability
of about 15% was associated with overlays being cost effective for
a range of willingness to pay values from £25 to £30 000 for an
extra pressure ulcer free day.
Sensitivity analyses
The results from the base case analysis were fairly robust to con-
sidering feasible variations in the life span of the pressure reliev-
ing surfaces or in changing provision between rental and
purchase. The three sensitivity analyses in table 3 suggest that
alternating pressure overlays are more costly and associated with
a more rapid development of new grade 2 pressure ulcers than
are alternating pressure mattresses.
Discussion
Alternating pressure mattresses to prevent pressure ulceration in
patients admitted to hospital are associated with lower costs and
greater benefits and are more likely to be cost saving than alter-
nating pressure overlays.
In this study we defined costs as mattress costs and hospital
costs. During the trial we observed that grade 2 pressure ulcers
did not usually receive dressings and other nursing care
therefore we did not estimate for further treatment costs.7 The
health benefits associated with the interventions were captured
as pressure ulcer free days. We chose this approach rather than
the more usual method of trying to capture a patient’s utility
through changes in quality of life because concurrent illness
would dominate any quality of life measurement. Furthermore,
the emphasis of our study was on prevention and participants
who developed new ulcers were not followed-up until the ulcer
healed. Although we did follow the healing of ulcers present at
baseline, we did not have quality of life data that related to the
time of ulceration (before admission) and therefore could not
examine how quality of life changes with the status of pressure
ulcers. The effect of pressure ulcer healing on people’s health
related quality of life may be the subject of future studies.
That the mattress is likely to be economically dominant may
initially seem counterintuitive. The mattress has a higher
purchase cost and no statistically significant effect on the
proportion of patients developing an ulcer, the time to
ulceration, the severity of ulcers, or length of stay. However, the
purchase cost of these pressure relieving surfaces is low when
viewed over their life span, and the difference in costs between
overlays and mattresses is small over this time period. For a two
year life span, the average cost per day would be £1.38 for an
Table 3 Economic evaluation of alternating pressure overlays compared
with alternating pressure mattresses for the prevention of pressure ulcers in
patients admitted to hospital
Overlay−mattress Mean (95% bias corrected confidence interval)
Base case analysis:
Differential health benefit (days) −10.64 (−24.40 to 3.09)
Differential cost (£) 283.60 (−377.59 to 976.79)
Sensitivity analyses:
Differential rental cost (£) 220.33 (−459.85 to 927.00)
Differential cost for five year life span
(£)
332.95 (−325.27 to 1020.77)
Differential cost for seven year life
span (£)
341.76 (−315.92 to 1028.63)
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Fig 1 Incremental cost effectiveness plane of using alternating pressure overlays or alternating pressure mattresses for the prevention of pressure ulcers in patients
admitted to hospital

































Fig 2 Cost effectiveness acceptability curve for alternating pressure mattresses
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overlay and £5.71 for a mattress (table 1). This cost difference is
small in the context of the daily inpatient treatment costs of
£165-£385 (depending on specialty) and the reduced length of
stay (on average, 1.22 of a day less) for mattress recipients in this
trial and translates into an average reduction in costs of £283.6
per patient. The health benefit associated with the interventions
was measured as the difference in mean time to develop a pres-
sure ulcer, and also favoured the mattress (on average by 10.64
days). The accompanying clinical paper for this trial reports the
median (rather than mean) time to ulceration, as is common
practice owing to the skewed distribution of time to event data.6
By contrast, and as recommended for economic analyses, we use
the mean time to pressure ulceration since the median would
greatly underestimate the costs.8 9
The delay in ulceration associated with alternating pressure
mattresses is crucial because the longer a patient avoids
ulceration the less likely they are to go on to develop a pressure
ulcer; a delay in ulceration allows the patient time to recover suf-
ficiently from their acute episode so that their risk of ulceration
recedes. We argue that although time to ulceration was a second-
ary end point in this trial, it should be considered as a primary
end point in future studies since it is more informative economi-
cally and clinically. Furthermore, many of the risk factors for
pressure ulceration in the participants do not completely disap-
pear on discharge from an acute hospital (for example, impaired
mobility), and simple proportions of pressure ulcers developed
ignore the censored nature of these data.
Total cost is a function of length of hospital stay which itself
is mainly a function of overall health status. Patients who are
more ill are both more at risk of pressure ulcers15 and likely to
have longer lengths of stay. It is probable that good nursing care,
such as the provision of a support surface, will completely
prevent pressure ulcers in a proportion of patients and will
merely delay the appearance of ulcers in others. If the
appearance of an ulcer is a proxy for acuity, and more acutely ill
patients consume more healthcare resources, then delays in
pressure ulceration suggest a potentially lower consumption of
healthcare resources. The longer length of stay in patients with
pressure ulcers is probably a consequence of comorbidities
rather than the pressure ulcer itself. We found no effect when we
tested to see whether the surfaces had a differential effect on
length of stay depending on the presence of a pressure ulcer;
overall lengths of stay for patients who developed a pressure
ulcer on either surface were similar.
Since there are no robust estimates of the cost of a pressure
ulcer we were not able to estimate the savings from pressure
ulcers prevented. Such a costing study would need to be large,
with a considerable length of follow-up, carried out in several
centres to ensure generalisability, and would require careful
observation of clinical practice in nursing care. It was not possi-
ble to undertake such a costing study within this trial.
Our results oppose those from the model based cost
effectiveness analysis by Fleurence because data in that trial were
based on expert opinion whereas we collected data within the
trial.16 Furthermore, the previous model disregarded the fact that
pressure ulcers are rarely the main reason for people being
admitted to hospital. Thus the marginal cost of treating a
pressure ulcer in hospital may be small compared with the over-
all costs of hospital treatment. In this sense our analysis reflects
actual practice. Our assumption that participants remained on
the allocated pressure relieving surface over their entire hospital
stay is a conservative one; in reality patients are moved on to
standard mattresses or higher specification surfaces after major
changes in their risk of pressure ulcers. Given participants in the
overlay group developed pressure ulcers earlier than those on
the mattresses, this assumption will have over-estimated the cost
of the mattresses, thus strengthening our conclusions.
Although neither the difference in mean overall hospital
costs nor the difference in mean time to development of
pressure ulcers between the two surfaces were statistically signifi-
cant, decision makers need to make a decision. Failing to do so
until statistically significant evidence becomes available would
deny patients the possibility of experiencing the expected health
benefits at an earlier stage and prevent the realisation of
expected savings to the NHS.9 Although there was considerable
uncertainty around the point estimates of mean health benefits
and costs shown in table 3, this should not result in large decision
uncertainty for decision makers since even for large willingness
to pay values (fig 2) the probability of the overlays being cost
effective is only between 10% and 20%.17
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sites in 16 countries, the initial merger of existing data-
bases has yielded a primary group of 2200 well charac-
terised patients with definite infective endocarditis by
the Duke criteria, allowing the assessment of regional
differences in presentation and outcome. Indeed,
analysis of the dataset has already enabled valuable
insight into emerging epidemiological patterns of the
disease and its clinical presentation.w18-w21 In future, this
platform will provide the basis for sorely needed
adequately sized randomised clinical trials in the man-
agement and treatment of infective endocarditis.w22 w23
The future
Several exciting developments offer the prospect of
improved prevention and treatment of infective endo-
carditis. Vaccines targeted at specific bacterial adhesins
may inhibit valve colonisation, and newer antibacterial
agents with novel effects may attenuate the invasive
properties of virulent organisms such as Staph aureus.1
Finally, modified biomaterials in development may
reduce the risk of infective endocarditis in patients with
artificial heart valves or other intracardiac prosthetic
material. However, despite these advances, the diagno-
sis and management of infective endocarditis remain a
considerable challenge across the range of medical
disciplines.
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Additional educational resources
Horstkotte D, Follath F, Gutschik E, Lengyel M, Oto A,
Pavie A, et al. Guidelines on prevention, diagnosis and
treatment of infective endocarditis: executive summary.
Eur Heart J 2004;25:267-76 (www.escardio.org/
knowledge/guidelines/)—A comprehensive document
covering all aspects of the investigation and manage-
ment of infective endocarditis
Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr,
Bolger AF, Levison ME, et al. Infective endocarditis:
diagnosis, antimicrobial therapy, and management of
complications. (circ.ahajournals.org/cgi/content/full/
111/23/e394)—Up to date American Heart Associa-
tion guidelines on the management of endocarditis
British National Formulary (www.bnf.org)—Detailed
explanation of current prophylaxis recommendations
International Collaboration on Endocarditis
(endocarditis.org/ice/index.html)
Information for patients
American Heart Association patient information sheet
(www.americanheart.org/
presenter.jhtml?identifier = 4436)—A good basic guide
written for non-medical personnel
American National Institute for Health information
sheet (www.nlm.nih.gov/medlineplus/ency/article/
000681.htm)—A brief description of infective endocar-
ditis from a patient’s perspective
Patient UK (www.patient.co.uk/showdoc/27000162/
)—A simple description of infective endocarditis from a
UK based site (partially funded by advertisements)
Corrections and clarifications
Pressure relieving support surfaces (PRESSURE) trial:
cost effectiveness analysis
This research article by Cynthia Iglesias and
colleagues (BMJ 2006;332:1416-8, 17 Jun) should
have included the trial registration identifier
Current Controlled Trials ISRCTN78646179.
Correction for Nixon et al
In the correction (BMJ 2006;333:30, 1 Jul) to the
article “Randomised, controlled trial of alternating
pressure mattresses compared with alternating
pressure overlays for the prevention of pressure
ulcers: PRESSURE (pressure relieving support
surfaces) trial” (BMJ 2006;332 1413-5, 17 Jun), we
incorrectly referred to haemoglobin levels rather
than odds ratios. We should have said: “In table 4 of
the full version on bmj.com (table 2 of the abridged
version), the odds ratio for haemoglobin levels on
admission or preoperatively should be 0.89 (0.82 to
0.97), and the corresponding P value should be 0.01.”
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